A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

计划入组 175 人 · 首次发布于 2023 年 10 月 30 日

Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)

计划入组 72 人 · 首次发布于 2025 年 6 月 10 日

Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study

计划入组 25 人 · 首次发布于 2025 年 9 月 23 日

Metabolic dysfunction-associated steatohepatitis(Cellarity)

siRNA therapy (sc, metabolic dysfunction-associated steatohepatitis)

undisclosed program

METABOLIC THERAPY, INC.

United States

Metabolic Technologies, Inc.

United States

Gt Metabolic Solutions, Inc.

United States

Madrigal's Resmetirom Nears Full Approval for NASH Cirrhosis Treatment Following Phase 3 Enrollment Completion

AI-Based Pathology Tool Validated for Scoring Metabolic Dysfunction-Associated Steatohepatitis

Multi-biotics Enhance Lenvatinib Sensitivity in MASH-Related HCC Organoids